Supplementary Figure 2: Expression analyses of protein-coding and lncRNA genes in TCGA samples.
From: Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
(a) Number of genes from GENCODE database v19. Expression was calculated in TCGA prostate cancer benign and tumor samples using the R Bioconductor package EdgeR. (b) Expression levels of lncRNAs are typically lower than those of protein-coding genes. (c) Lower expression is typical in all samples, and more abundant genes have comparatively higher expression. (d) Distribution of abundance of lncRNAs and protein-coding genes in TCGA prostate cancer samples. The y axis is limited to a maximum of 1,000 genes. (e) Number of lncRNAs above the threshold for different statistics. The statistics were calculated using all lncRNAs that were expressed in at least 50% of the clinical samples. CPM, count per million; lncRNA, long noncoding RNA; PCG, protein-coding gene.
